Petros Pharmaceuticals Inc. (NASDAQ:PTPI) went up by 5.15% from its latest closing price compared to the recent 1-year high of $5.20. The company’s stock price has collected -14.88% of loss in the last five trading sessions. Press Release reported on 12/28/21 that Petros Pharmaceuticals Announces Closing of $7.5 Million Offering
Is It Worth Investing in Petros Pharmaceuticals Inc. (NASDAQ :PTPI) Right Now?
Opinions of the stock are interesting as 0 analysts out of 0 who provided ratings for Petros Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
Today, the average trading volume of PTPI was 18.00M shares.
PTPI’s Market Performance
PTPI stocks went down by -14.88% for the week, with a monthly jump of 21.19% and a quarterly performance of 75.78%, while its annual performance rate touched -35.59%. The volatility ratio for the week stands at 14.47% while the volatility levels for the past 30 days are set at 21.16% for Petros Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -12.32% for PTPI stocks with a simple moving average of 4.59% for the last 200 days.
PTPI Trading at 8.99% from the 50-Day Moving Average
After a stumble in the market that brought PTPI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.00% of loss for the given period.
Volatility was left at 21.16%, however, over the last 30 days, the volatility rate increased by 14.47%, as shares surge +5.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +67.25% upper at present.
During the last 5 trading sessions, PTPI fell by -14.88%, which changed the moving average for the period of 200-days by -21.64% in comparison to the 20-day moving average, which settled at $3.27. In addition, Petros Pharmaceuticals Inc. saw -14.11% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at PTPI starting from SHULMAN JOHN D, who purchase 145,773 shares at the price of $3.43 back on Dec 22. After this action, SHULMAN JOHN D now owns 5,703,544 shares of Petros Pharmaceuticals Inc., valued at $500,001 using the latest closing price.
SHULMAN JOHN D, the Director of Petros Pharmaceuticals Inc., purchase 500,000 shares at $3.00 during a trade that took place back on Nov 29, which means that SHULMAN JOHN D is holding 5,557,771 shares at $1,500,000 based on the most recent closing price.
Stock Fundamentals for PTPI
Current profitability levels for the company are sitting at:
- -180.78 for the present operating margin
- -12.00 for the gross margin
The net margin for Petros Pharmaceuticals Inc. stands at -215.35. The total capital return value is set at -72.34, while invested capital returns managed to touch -122.10.
Based on Petros Pharmaceuticals Inc. (PTPI), the company’s capital structure generated 44.73 points at debt to equity in total, while total debt to capital is 30.91. Total debt to assets is 11.19, with long-term debt to equity ratio resting at 3.04. Finally, the long-term debt to capital ratio is 2.10.
When we switch over and look at the enterprise to sales, we see a ratio of 4.14, with the company’s debt to enterprise value settled at 0.23. The receivables turnover for the company is 2.46 and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.62.